"A new state-of-the-art facility dedicated to pediatric cardiac imaging and intervention, co-established by the National Institutes of Health and Children's National Medical Center, was opened with a special dedication ceremony today. The new faci"...
Procardia XL (nifedipine extended release tablets) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Procardia XL (nifedipine extended release tablets) may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers.
Chronic Stable Angina (Classical Effort-Associated Angina)
Procardia XL (nifedipine extended release tablets) is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.
In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete.
Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (See WARNINGS).
Procardia XL (nifedipine extended release tablets) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
DOSAGE AND ADMINISTRATION
Dosage must be adjusted according to each patient's needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily. Procardia XL Extended Release Tablets should be swallowed whole and should not be bitten or divided. In general, titration should proceed over a 7-14 day period so that the physician can fully assess the response to each dose level and monitor blood pressure before proceeding to higher doses. Since steady-state plasma levels are achieved on the second day of dosing, titration may proceed more rapidly, if symptoms so warrant, provided the patient is assessed frequently. Titration to doses above 120 mg are not recommended.
Angina patients controlled on Procardia capsules alone or in combination with other antianginal medications may be safely switched to Procardia XL (nifedipine extended release tablets) Extended Release Tablets at the nearest equivalent total daily dose (e.g., 30 mg t.i.d. of Procardia capsules may be changed to 90 mg once daily of Procardia XL (nifedipine extended release tablets) Extended Release Tablets). Subsequent titration to higher or lower doses may be necessary and should be initiated as clinically warranted. Experience with doses greater than 90 mg in patients with angina is limited. Therefore, doses greater than 90 mg should be used with caution and only when clinically warranted.
No “rebound effect” has been observed upon discontinuation of Procardia XL Extended Release Tablets. However, if discontinuation of nifedipine is necessary, sound clinical practice suggests that the dosage should be decreased gradually with close physician supervision.
Care should be taken when dispensing Procardia XL (nifedipine extended release tablets) to assure that the extended release dosage form has been prescribed.
Co-Administration with Other Antianginal Drugs
Sublingual nitroglycerin may be taken as required for the control of acute manifestations of angina, particularly during nifedipine titration. See PRECAUTIONS: DRUG INTERACTIONS, for information on co-administration of nifedipine with beta blockers or long-acting nitrates.
Procardia XL (nifedipine extended release tablets) Extended Release Tablets are supplied as 30 mg, 60 mg and 90 mg round, biconvex, rose-pink, film-coated tablets in:
Bottles of 100:
30 mg (NDC 0069-2650-66)
60 mg (NDC 0069-2660-66)
90 mg (NDC 0069-2670-66)
Bottles of 300:
30 mg (NDC 0069-2650-72)
60 mg (NDC 0069-2660-72)
Unit dose packages of 100:
30 mg (NDC 0069-2650-41)
60 mg (NDC 0069-2660-41)
Store below 86°F (30°C).
Protect from moisture and humidity.
Distributed by: Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. Revised February 2010
Last reviewed on RxList: 11/2/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Procardia XL Information
Procardia XL - User Reviews
Procardia XL User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.